Shots:
- SERB Pharmaceuticals has entered into a definitive merger agreement to acquire Y-mAbs, incl. its asset Danyelza (naxitamab-gqgk), strengthening its rare oncology portfolio
- As per the deal, SERB will acquire Y-mAbs for a total equity value of ~$412M, with its shareholders receiving $8.6/share in cash, delisting Y-mAbs from Nasdaq; closing expected in Q4’25
- Additionally, Y-mAbs’ pipeline incl. an investigational P-I therapy from its SADA PRIT platform, targeting GD2 in solid tumors & CD38 in circulating tumors using pre-targeted radioimmunotherapy
Ref: Globe Newswire | Image: Y-mAbs Therapeutics | Press Release
Related News:- Alcon to Acquire STAAR Surgical Company for ~$1.5B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
